Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27,767,902
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
12,779,810
-
Shares change
-
+165,419
-
Total reported value, excl. options
-
$597,980,830
-
Value change
-
+$18,398,348
-
Put/Call ratio
-
30%
-
Number of buys
-
67
-
Number of sells
-
-46
-
Price
-
$46.80
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2017
138 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2017.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12,779,810 shares
of 27,767,902 outstanding shares and own 46% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2,246,539 shares), Krensavage Asset Management, LLC (1,013,847 shares), FIRST MANHATTAN CO (947,100 shares), VANGUARD GROUP INC (837,563 shares), STATE STREET CORP (720,999 shares), Invesco Ltd. (703,460 shares), RENAISSANCE TECHNOLOGIES LLC (681,100 shares), DIMENSIONAL FUND ADVISORS LP (562,394 shares), FARALLON CAPITAL MANAGEMENT LLC (412,333 shares), and Stonepine Capital Management, LLC (390,000 shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.